m+Medelevator.RU
← Поиск публикаций
Journal of the National Comprehensive Cancer Network : JNCCN · 2025

Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology.

СтатьяКлинические рекомендацииНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Bordeaux Jeremy, Blitzblau Rachel, Aasi Sumaira Z, Alam Murad, Amini Arya, Bibee Kristin, Bolotin Diana, Chen Pei-Ling, Contreras Carlo M, DiMaio Dominick, Donigan Jessica M, Farma Jeffrey M, Ghosh Karthik, Harms Kelly, LeBoeuf Nicole, Lukens John Nicholas, Manber Susan, Mark Lawrence, Medina Theresa, Nehal Kishwer S, Nghiem Paul, Olino Kelly, Paragh Gyorgy, Park Soo, Patel Tejesh, Rich Jason, Shaha Ashok R, Sharma Bhavina, Sokumbi Yemi, Srivastava Divya, Thomas Valencia, Tomblinson Courtney, Venkat Puja, Xu Yaohui Gloria, Yu Siegrid, Yusuf Mehran, McCullough Beth, Espinosa Sara

Аннотация

SUMMARY: We present a rare case of a 19-month-old boy with trisomy 13 who initially presented with hyperinsulinemic hypoglycemia (HH) at 1 month of age and later developed type 1 diabetes mellitus (T1DM). While cases of HH or T1DM alone have been reported in trisomy 13 patients, this is the first known report of both conditions occurring sequentially in a single individual. No previous reports have described the sequential progression from HH to T1DM in any population, highlighting this as an unprecedented clinical observation. This case underscores the complex nature of metabolic disorders in trisomy 13 and provides insights into the underlying mechanisms linking this chromosomal anomaly to the development of both HH and T1DM.

LEARNING POINTS: Sequential progression from HH to T1DM in both trisomy 13 and the general population is unprecedented. The coexistence and progression of HH and T1DM underscore the intricate and multifaceted nature of metabolic disorders in trisomy 13. Routine monitoring of blood glucose and C-peptide levels may facilitate the detection of metabolic transitions in patients with trisomy 13.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты